PFKFB1/PFKFB4 Antibody

What are PFKFB1 and PFKFB4 enzymes and what is their biological significance?

PFKFB1 and PFKFB4 are members of the bifunctional 6-phosphofructo-2-kinase:fructose-2,6-biphosphatase enzyme family. These enzymes form homodimers that catalyze both the synthesis and degradation of fructose-2,6-biphosphate using independent catalytic domains. Fructose-2,6-biphosphate functions as an activator of the glycolysis pathway and an inhibitor of the gluconeogenesis pathway, making these enzymes crucial regulators of glucose homeostasis . PFKFB4 specifically plays critical roles in metabolic processes and has been implicated in cancer cell proliferation and metastasis .

What are the typical applications for PFKFB1/PFKFB4 antibodies in research?

PFKFB1/PFKFB4 antibodies are commonly used in:

• Western Blot (WB): For detecting endogenous levels of total PFKFB1/4 proteins with recommended dilutions ranging from 1:500-1:4000

• Immunohistochemistry (IHC): For tissue localization studies with dilutions typically between 1:50-1:500

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization with dilutions of 1:200-1:800

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative protein detection

How should PFKFB1/PFKFB4 antibodies be stored and handled for optimal performance?

For optimal antibody performance and longevity:

• Store at -20°C or -80°C, depending on manufacturer recommendations

• Avoid repeated freeze-thaw cycles as they may compromise antibody activity

• Most preparations are supplied in PBS with stabilizing agents such as glycerol (typically 50%) and preservatives like sodium azide (0.02%)

• Working solutions should be prepared fresh when possible

• Liquid formulations are typically stable for one year after shipment when stored properly

How can researchers validate the specificity of PFKFB1/PFKFB4 antibodies for their experimental systems?

Comprehensive validation approaches should include:

• Positive controls: Use cell lines with known expression such as HepG2, MDA-MB-231, PC-3, and Raji cells for Western blot applications

• Molecular weight verification: Confirm detection at the expected molecular weight (~54 kDa for PFKFB4)

• Knockdown/overexpression validation: Compare antibody signals in cells with genetically manipulated expression levels of PFKFB1/4 (e.g., stable 231 PFKFB4 cell lines as described in published studies)

• Tissue specificity: Test reactivity in tissues known to express the target (e.g., human kidney tissue, mouse testis tissue for PFKFB4)

• Cross-reactivity assessment: Test antibody performance across multiple species when working with non-human models

What are the critical considerations for optimizing immunohistochemistry protocols when using PFKFB1/PFKFB4 antibodies?

For optimal IHC results with PFKFB1/PFKFB4 antibodies:

• Antigen retrieval: Studies suggest using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may serve as an alternative

• Antibody concentration: Titration experiments are recommended, with typical starting dilutions of 1:50-1:500

• Incubation conditions: Optimize both temperature and duration (overnight at 4°C versus 1-2 hours at room temperature)

• Detection system selection: Choose amplification systems appropriate for the expected expression level

• Controls: Include both positive controls (tissues with known expression) and negative controls (primary antibody omission)

• Counterstaining: Consider light hematoxylin counterstaining to visualize tissue architecture without obscuring specific staining

How can researchers troubleshoot Western blot problems specific to PFKFB1/PFKFB4 detection?

When troubleshooting Western blot detection issues:

• Sample preparation: Ensure complete protein extraction using buffers containing phosphatase inhibitors if studying phosphorylation states

• Protein loading: Load 20-50 μg of total protein per lane; adjust based on expression levels

• Transfer efficiency: Verify with reversible staining methods (Ponceau S)

• Blocking optimization: Test alternative blocking agents if high background is observed

• Antibody incubation: Consider extended primary antibody incubation (overnight at 4°C) to improve sensitivity

• Signal enhancement: Use appropriate detection systems; chemiluminescence may be preferable for low abundance targets

• Cross-reactivity: If detecting both PFKFB1 and PFKFB4 simultaneously, confirm band specificity through additional validation steps

How are PFKFB1/PFKFB4 antibodies used to study hypoxia-induced metabolic changes in cancer cells?

PFKFB4 has been demonstrated to be upregulated under hypoxic conditions in cancer cells. Research approaches include:

• Hypoxia induction models: Treatments can induce elevated levels of HIF-1α and subsequent PFKFB4 expression in cell lines such as MDA-MB-231

• Comparative antibody analysis: Researchers can compare PFKFB4 expression between normoxic and hypoxic conditions using western blotting with antibody dilutions of 1:1000-1:3000

• Co-localization studies: IF/ICC techniques can reveal subcellular localization changes under hypoxic stress

• Time-course experiments: Antibodies can track temporal expression patterns following hypoxic exposure

• Correlation with glycolytic markers: Combine PFKFB4 detection with analysis of other glycolytic enzymes to establish metabolic profiles

Published studies have shown that the testis isoform of PFKFB4 protein is expressed in Triple-Negative Breast Cancer (TNBC) cells and that hypoxic induction of PFKFB4 protein expression is mediated by HIF-1α .

What approaches can be used to study the non-glycolytic functions of PFKFB4 using specific antibodies?

Recent research has revealed novel non-glycolytic functions of PFKFB4, particularly in cell migration and signaling. Methodological approaches include:

• Protein-protein interaction studies: Co-immunoprecipitation experiments using PFKFB4 antibodies to identify interacting partners such as ICMT in melanoma cells

• Subcellular fractionation: Combined with Western blot to determine compartment-specific localization and function

• Immunofluorescence co-localization: With RAS pathway components to study membrane localization and signaling

• Phosphoprotein analysis: Examine downstream AKT signaling activation using phospho-specific antibodies in conjunction with PFKFB4 detection

• Migration assays: Correlate PFKFB4 expression with migration phenotypes while controlling for glycolytic activity

Studies have demonstrated that PFKFB4 interacts with ICMT (a posttranslational modifier of RAS), promotes ICMT/RAS interaction, controls RAS localization at the plasma membrane, activates AKT signaling, and enhances cell migration in a glycolysis-independent manner .

How can PFKFB1/PFKFB4 antibodies be used in studying the relationship between metabolism and tumor microenvironment?

To investigate the complex interplay between PFKFB4-mediated metabolism and the tumor microenvironment:

• Multiplex immunohistochemistry: Combine PFKFB4 antibodies with markers for immune cell infiltration to correlate expression with immune cell populations

• Spatial transcriptomics integration: Correlate protein expression patterns with gene expression signatures in specific tissue regions

• Ex vivo tissue culture models: Treat with metabolic inhibitors and assess changes using PFKFB4 antibodies

• Orthotopic xenograft models: Compare PFKFB4 expression between in vitro and in vivo conditions using IHC

• Single-cell analysis: Combine with flow cytometry to identify cell-specific expression patterns

Research has shown correlations between PFKFB4 expression and infiltration of diverse immune cell types in colon adenocarcinoma patients, including CD8+ T cells, CD4+ T cells, regulatory T cells, macrophages, neutrophils, dendritic cells, active mast cells, and resting NK cells .

How should researchers design experiments to investigate PFKFB4's role in cancer progression?

A comprehensive experimental approach would include:

• Expression profiling: Use antibodies to compare PFKFB4 levels across normal tissues, primary tumors, and metastatic lesions

• Genetic manipulation studies: Combine overexpression and knockdown approaches with antibody detection to validate phenotypes

• In vivo models: Inject cells with varying PFKFB4 expression levels into appropriate animal models and monitor tumor growth

• Drug response experiments: Examine how PFKFB4 levels correlate with therapeutic response (e.g., cisplatin resistance)

• Cell cycle analysis: Correlate PFKFB4 expression with cell cycle markers like Ki67 and CDK6

• Glycolytic flux measurements: Pair with metabolic assays to distinguish between metabolic and non-metabolic functions

Published research using this approach has shown that PFKFB4 overexpression promoted tumor growth in vivo, with 231 PFKFB4 group tumors reaching volumes of 712.5 ± 253.7 mm³ by day 35, significantly larger than control groups (207.9 ± 102.0 mm³ and 153.1 ± 62.7 mm³) .

What considerations are important when analyzing seemingly contradictory findings about PFKFB4 expression and patient outcomes?

When reconciling conflicting data:

• Context-specific expression analysis: Use antibodies to delineate tissue-specific or cancer subtype-specific patterns

• Stage-dependent effects: Stratify samples by disease stage when analyzing correlations with survival

• Isoform-specific detection: Ensure antibodies can distinguish between alternatively spliced variants

• Companion biomarker analysis: Correlate PFKFB4 with other markers that might explain contextual differences

• Multivariate statistical approaches: Control for confounding variables when assessing prognostic value

How can researchers assess the specificity of antibodies that target both PFKFB1 and PFKFB4?

To ensure accurate interpretation when using antibodies targeting both isoforms:

• Isoform-specific controls: Test against recombinant proteins of each isoform

• Isoform-selective knockdown: Use siRNA against each isoform separately to identify band specificity

• Tissue distribution validation: Compare detection patterns against known differential expression profiles (e.g., PFKFB1 in liver, PFKFB4 in testis)

• Peptide competition assays: Use isoform-specific blocking peptides to confirm antibody specificity

• Mass spectrometry validation: Confirm antibody-detected bands through proteomic identification

• Cross-reactivity assessment: Test against all four PFKFB family members (PFKFB1-4)

Commercial antibodies like the Invitrogen™ PFKFB1/PFKFB4 Polyclonal Antibody (PA5104524) are designed to detect endogenous levels of total PFKFB1/4 , making these validation steps crucial for precise experimental interpretation.

What methodological approaches can identify transcriptional regulators of PFKFB4 using antibody-based techniques?

To investigate transcriptional regulation of PFKFB4:

• Chromatin immunoprecipitation (ChIP): Use antibodies against potential transcription factors like SP1 and HIF-1α along with PFKFB4 promoter-specific primers

• ChIP-sequencing: Genome-wide approaches to identify novel transcription factor binding sites

• Dual-luciferase reporter assays: Validate binding interactions using wild-type and mutant PFKFB4 promoter constructs

• Co-immunoprecipitation: Determine physical interactions between transcription factors and co-activators

• Histone modification analysis: Use antibodies against specific modifications (e.g., H3K9me2) to assess epigenetic regulation

Research has identified that KDM3A enhances SP1 transcription by demethylating H3K9me2 on its promoter, and SP1 subsequently binds to the PFKFB4 promoter to activate its transcription. This KDM3A-SP1-PFKFB4 axis promotes aerobic glycolysis in osteosarcoma and augments tumor development .

How can researchers investigate post-translational modifications of PFKFB4 using antibody-based approaches?

For studying post-translational modifications:

• Phospho-specific antibodies: Develop or obtain antibodies targeting specific phosphorylation sites

• IP-Mass spectrometry: Immunoprecipitate PFKFB4 and analyze for modifications using mass spectrometry

• 2D gel electrophoresis: Combine with Western blotting to separate modified forms

• Proximity ligation assay: Detect interactions between PFKFB4 and modifying enzymes in situ

• FRET-based approaches: Study dynamic modification changes in living cells

Understanding post-translational modifications is crucial as PFKFB4 has been shown to function as a protein kinase that can phosphorylate other proteins, suggesting complex regulatory mechanisms .

What novel methodological approaches combine metabolomics with PFKFB4 antibody-based detection for integrated analysis?

Integrated metabolomic approaches include:

• Spatial metabolomics with IHC: Correlate metabolite distributions with PFKFB4 expression in tissue sections

• Stable isotope tracing: Combine with immunoprecipitation to track metabolic flux through PFKFB4-associated pathways

• Single-cell metabolomics: Integrate with antibody-based cell sorting to define metabolic phenotypes

• Metabolic inhibitor studies: Combine pharmacological manipulation with antibody detection to establish causality

• In situ metabolic profiling: Use metabolic sensors combined with immunofluorescence for co-localization studies

These integrated approaches can help elucidate the connections between PFKFB4 expression and various metabolic pathways identified in bioinformatic analyses, including amino acid biosynthesis, glycolysis, gluconeogenesis, glucose metabolism, and inflammatory response .